drugset / Trial / NCT03879382
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.
Timeline
- Start
- 2019-02-27
- Primary completion
- 2020-08-30
- Completion
- 2022-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19/BCMA CAR-T cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |